Betaglue technologies strengthen its expertise in strategic areas with four new managers

• Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas
• Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated

Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, announces the appointment of four new managers, strengthening the team across strategic areas for its business development.
Betty Polikar, Gianluca Danieli, Pietro Bubba Bello, and Gaia Bisaccioni joined the company in September in the Clinical Research, Manufacturing, and Quality areas.

Betty Polikar was Head of the Startup Unit of the Center of Excellence at "Bambino Gesii" Children`s Hospital in Rome and will now bring her experience as Head of Clinical Operations of BetaGlue. Gianluca De Danieli is taking on the role of Head of Clinical Development, Pietro Bubba Bello will be Head of Manufacturing & Operations, ard Gaia Bisaccioni is joining the company as Head of Quality. The three managers join the company from Novartis, after having worked at Advanced Accelerator Applications (AAA), a company that has pioneered the nuclear medicine revolution, following its recent €3.9 billion acquisition.

At the same time, clinical progresses are ongoing for BAT-90, the advanced cancer radiotherapy platform developed by BetaGlue: on September 29, 2022, the first breast cancer patient was treated at New Hospitals in Tblisi, Georgia. This is the second "first in man" clinical trial, after the one in liver cancer patients (hepatocarcinoma, please see the July 11, 2022 press release).

Such developments were also made possible by the successful closing of the €10 million equity financing round by Fin Posillipo (Petrone Group), Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaolo Group), Profequycapital and Romed, with a reinvestment from existing investors Innogest Capital and Panakes Partners (please see press release of July 19, 2022).

Riccardo Palmisano, Executive Chairman, and Antonino Amato, CEO/CMO of BetaClue Technologies, declared: `The appointment of four new highly skilled leaders with proven experience in Life Sciences` key areas, along with the increased financial assets stemming from the successful closing of our recent financing round, enables BetaClue to continue with confidence toward achieving the ambitious goal of creating value for both Patients and Shareholders".